|
|
|
|
 |
|
SENSEX
|
 |
-445.59
|
-0.62%
|
|
71580.56
|
|
|
|
NIFTY
|
|
-133.60
|
-0.62%
|
|
21577.20
|
|
|
|
Nasdaq
|
 |
13.77
|
0.09%
|
|
14524.07
|
|
|
|
Nikkei 225
|
|
89.13
|
0.27%
|
|
33377.42
|
|
|
|
FTSE 100
|
|
-33.50
|
-0.43%
|
|
7689.60
|
|
|
 |
|
|
|
|
|
|
|
|
YOU ARE ON
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
Glenmark Life Sciences Ltd.
|
|
|
|
04-01-2024
|
|
|
|
| Significant increase in volume has been observed in Glenmark Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Glenmark Life Sciences Limited has submitted their response. |
|
|
|
|
|
04-01-2024
|
|
|
|
| Significant increase in volume has been observed in Glenmark Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is |
|
|
|
|
|
03-01-2024
|
|
|
|
| Significant increase in volume has been observed in Glenmark Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Glenmark Life Sciences Limited has submitted their response. |
|
|
|
|
|
03-01-2024
|
|
|
|
| Significant increase in volume has been observed in Glenmark Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |
|
|
|
|
|
02-01-2024
|
|
|
|
| Significant increase in volume has been observed in Glenmark Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |
|
|
|
|
|
02-01-2024
|
|
|
|
| Significant increase in volume has been observed in Glenmark Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is |
|
|
|
|
|
13-11-2023
|
|
|
|
| Monitoring Agency Report for the Quarter ended 30th September, 2023 |
|
|
|
|
|
26-10-2023
|
|
|
|
| Glenmark Life Sciences Limited has informed the Exchange about Transcript |
|
|
|
|
|
25-10-2023
|
|
|
|
| Glenmark Life Sciences Limited has informed the Exchange about Transcript |
|
|
|
|
|
20-10-2023
|
|
|
|
| Glenmark Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2023. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|